Purpose Oral anticoagulants are crucial for preventing systemic thromboembolism in atrial
fibrillation (AF), with guidelines preferring non-vitamin K antagonist oral anticoagulants …

The prevalence of both atrial fibrillation (AF) and obesity has steadily increased. Nonvitamin
K antagonist oral anticoagulants (NOACs) have been shown to be more effective and safer …

Background and aim Atrial fibrillation (AF) is the most frequently observed cardiac
arrhythmia in clinical settings. Obesity can influence the efficacy of the treatment …

Background There is a paucity of evidence regarding the effects of non-vitamin K antagonist
oral anticoagulants (NOACs) in underweight patients with atrial fibrillation (AF). Objective …

BACKGROUND: The efficacy and safety of non–vitamin-K antagonist oral anticoagulants
(NOACs) across the spectrum of body mass index (BMI) and body weight (BW) remain …

Aims We conducted a systematic review and meta-analysis on three outcomes. We
assessed the efficacy and safety of direct oral anticoagulants (DOAC) compared to vitamin K …

Highlights•Obesity is an important risk factor for atrial fibrillation.•Despite “obesity paradox”
in atrial fibrillation, patient weight loss preferred.•Oral anticoagulants may be more …

Aims This study sought to determine the impact of weight and body mass index (BMI) on the
safety and efficacy of direct-acting oral anticoagulants (DOACs) compared with warfarin in …

Background and Purpose—Obesity is a risk factor for all-cause and cardiovascular death
but, despite this, an inverse relationship between overweight or obesity and a better …

Objectives Concerns have arisen recently over the relationship between body mass index
(BMI) and outcomes in atrial fibrillation (AF) patients with direct oral anticoagulants (DOACs) …